Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (CrossMab) (CROSSAB-H303)

Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (CrossMab) is designed to be expressed as four chains with knobs-into-holes mutations and domain crossover. After one or multi-steps purification, high-purity antibody can be obtained. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.

Datasheet

Specifications

Targets

CD89 & EGFR

Type

CrossMab

Species Reactivity

Human

Target 1

CD89

Host Animal 1

Human

Target 2

EGFR

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors

Targets

Target 1

CD89

Gene ID

2204

UniProt ID

P24071

Alternative Names

FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor

Target 2

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: